0001615055FALSE00016150552022-09-122022-09-12


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 12, 2022
IsoPlexis Corporation
(Exact name of registrant as specified in its charter)

Delaware001-4089446-2179799
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
35 NE Industrial Road, Branford, CT 06405
(Address of principal executive offices and zip code)
(203) 208-4111
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common Stock, par value $0.001 per
share
ISOThe Nasdaq Stock Market LLC
    
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 7.01. Regulation FD Disclosure.

On September 12, 2022 at 4:50 p.m. Eastern Time, the Company is participating in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York, New York. In connection with such presentation, the Company is posting an investor slide deck to its website at www.isoplexis.com, a copy of which is furnished herewith as Exhibit 99.1.

The information furnished in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.




Item 9.01. Financial Statements and Exhibits
(d) Exhibits
Exhibit No.
Description
104Cover Page Interactive Data File (embedded within the Inline XBRL document)




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ISOPLEXIS CORPORATION
Date: September 12, 2022
By:/s/ John Strahley
Name:John Strahley
Title:Chief Financial Officer












IsoPlexis (NASDAQ:ISO)
Historical Stock Chart
Von Dez 2024 bis Jan 2025 Click Here for more IsoPlexis Charts.
IsoPlexis (NASDAQ:ISO)
Historical Stock Chart
Von Jan 2024 bis Jan 2025 Click Here for more IsoPlexis Charts.